AJANTA PHARMA
|
AJANTA PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 46.70 | 83.45 | 75.59 | 53.60 | 44.35 |
| CEPS(Rs) | 57.09 | 65.42 | 59.34 | 43.05 | 35.08 |
| DPS(Rs) | 7.00 | 9.50 | 9.50 | 13.00 | 9.00 |
| Book NAV/Share(Rs) | 269.07 | 382.20 | 346.24 | 297.80 | 257.19 |
| Tax Rate(%) | 21.10 | 21.64 | 27.36 | 29.56 | 24.75 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.64 | 27.37 | 33.85 | 26.40 | 27.56 |
| EBIT Margin(%) | 19.79 | 27.09 | 30.80 | 26.12 | 25.08 |
| Pre Tax Margin(%) | 19.63 | 26.78 | 30.52 | 25.66 | 25.02 |
| PAT Margin (%) | 15.49 | 20.99 | 22.17 | 18.07 | 18.83 |
| Cash Profit Margin (%) | 18.94 | 24.68 | 26.10 | 21.77 | 22.33 |
| Performance Ratios | |||||
| ROA(%) | 13.21 | 17.16 | 17.03 | 14.44 | 14.52 |
| ROE(%) | 17.68 | 22.77 | 23.38 | 19.32 | 18.07 |
| ROCE(%) | 22.57 | 29.37 | 32.20 | 27.44 | 23.84 |
| Asset Turnover(x) | 0.85 | 0.82 | 0.77 | 0.80 | 0.77 |
| Sales/Fixed Asset(x) | 1.69 | 1.56 | 1.43 | 1.46 | 1.37 |
| Working Capital/Sales(x) | 2.25 | 2.10 | 2.14 | 2.50 | 2.56 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.59 | 0.64 | 0.70 | 0.69 | 0.73 |
| Receivable days | 99.85 | 94.50 | 93.66 | 87.08 | 81.62 |
| Inventory Days | 77.25 | 83.71 | 78.09 | 65.68 | 69.82 |
| Payable days | 157.44 | 188.77 | 260.89 | 199.39 | 293.02 |
| Valuation Parameters | |||||
| PER(x) | 25.89 | 14.45 | 15.82 | 16.99 | 15.49 |
| PCE(x) | 21.18 | 18.44 | 20.15 | 21.16 | 19.58 |
| Price/Book(x) | 4.49 | 4.73 | 5.18 | 4.59 | 4.01 |
| Yield(%) | 0.58 | 0.53 | 0.53 | 0.95 | 0.87 |
| EV/Net Sales(x) | 3.98 | 4.56 | 5.30 | 4.54 | 4.34 |
| EV/Core EBITDA(x) | 16.89 | 14.58 | 14.94 | 15.16 | 15.19 |
| EV/EBIT(x) | 19.83 | 16.57 | 16.85 | 17.40 | 17.32 |
| EV/CE(x) | 3.17 | 3.63 | 3.72 | 3.29 | 3.07 |
| M Cap / Sales | 4.07 | 4.62 | 5.37 | 4.61 | 4.37 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.02 | 15.62 | 11.66 | 25.91 | -3.31 |
| Core EBITDA Growth(%) | -15.61 | 1.99 | 32.11 | 32.00 | -13.92 |
| EBIT Growth(%) | -18.33 | 1.24 | 34.41 | 31.13 | -17.26 |
| PAT Growth(%) | -17.50 | 8.99 | 39.81 | 20.86 | -17.43 |
| EPS Growth(%) | -44.04 | 10.40 | 41.02 | 20.86 | -16.72 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | 0.02 | 0.02 |
| Current Ratio(x) | 2.48 | 3.50 | 2.64 | 2.39 | 2.61 |
| Quick Ratio(x) | 1.77 | 2.31 | 1.74 | 1.73 | 1.80 |
| Interest Cover(x) | 128.61 | 90.16 | 109.85 | 56.75 | 444.34 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of AJANTA PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AJANTA PHARMA | ₹26,183.4 Cr | 5.4% | 4.4% | 78.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,015.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,809.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,408.7 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹98,684.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹94,213.7 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
AJANTA PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AJANTA PHARMA | 5.4% |
4.4% |
78.1% |
| SENSEX | -2.9% |
-0.4% |
20% |
You may also like the below Video Courses
